Bromantane

Actoprotector (Ladasten)

Bromantane (Actoprotector (Ladasten)) is a cognitive & mood research compound. Actoprotector — mildly upregulates dopamine synthesis (tyrosine hydroxylase) while being anxiolytic; energy and endurance without classic stimulant crash.

How Bromantane works

Actoprotector — mildly upregulates dopamine synthesis (tyrosine hydroxylase) while being anxiolytic; energy and endurance without classic stimulant crash.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Bromantane

Bromantane is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.

The evidence for Bromantane

Graded by what exists behind each claim.

Human clinical evidence

• The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.

📊 Correlative data

• Developed as a Soviet military 'actoprotector' and later registered in Russia as Ladasten for asthenia. Russian trials report improved fatigue and mood without the rebound of conventional stimulants.
• It is banned by WADA, which is a useful independent signal that it does something — nobody bothers prohibiting an inert compound. Reported experience is of a slow-building, non-jittery energy over days.

🧪 Theoretical / extrapolated

• An adamantane derivative that increases dopamine synthesis by upregulating tyrosine hydroxylase and DOPA decarboxylase expression — rather than releasing or blocking reuptake of existing dopamine.
• That distinction explains the reported absence of a crash. Releasing agents deplete a pool and you pay for it later; increasing synthesis raises the pool itself. It also predicts the slow onset, since transcriptional changes take days.

How to read the Soviet clinical series →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Bromantane actually does

Bromantane is N-(2-adamantyl)-N-(para-bromophenyl)-amine Mikhaylova 2007 — an adamantane cage, the same rigid hydrocarbon skeleton carried by amantadine and memantine, joined through a secondary amine to a bromobenzene ring. That structure tells you two things before any pharmacology: it is very lipophilic, and it belongs to a chemical family with a history of dopaminergic and NMDA-channel activity.

What it does is not what stimulants do, and the distinction is the whole compound. Amphetamines release stored dopamine; methylphenidate blocks its reuptake. Both spend an existing pool. Mikhaylova 2007 gave rats a single 50 mg/kg oral dose and measured catecholamine biosynthesis in the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus, and found that ladasten differentially regulates tyrosine hydroxylase messenger RNA and protein, along with dopamine and L-DOPA content. Tyrosine hydroxylase is the rate-limiting enzyme of catecholamine synthesis. Changing how much of it a neuron makes is a transcriptional intervention on the supply side, not a pharmacological squeeze on the existing store — and that predicts a slow onset, no acute spike and no crash on stopping.

The second finding is stranger and more interesting. In hippocampal slices, 10 micromolar ladasten converted short-term potentiation of synaptic transmission into a long-lasting form. It also did so when applied 40 minutes after a single 100 Hz, 200 ms tetanization — that is, after the synaptic event had already happened. The reinforcement was blocked by the protein synthesis inhibitor anisomycin and attenuated by the D1/D5 antagonist SCH23390 Mikhaylova 2007. So the mechanism is retroactive consolidation of an existing trace, dependent on new protein synthesis and on dopamine D1/D5 signaling.

That is a specific and unusual claim: a drug that does not create the memory but decides whether one that already formed becomes permanent. If it holds in a person, the dosing logic is inverted from every nootropic on the shelf — you would take it after the work, not before.

The third strand is immune. Tallerova 2011 reported that ladasten reduced the proinflammatory cytokines TNF-alpha and IL-6 in mice with an experimental depression-like syndrome, and did so more potently than imipramine. Whether that is a separate action or downstream of the dopaminergic one is unresolved, and it is the reason the Russian literature frames this compound as an ‘actoprotector’ — a fatigue-resistance agent — rather than as a stimulant.

Cell, rodent, human — and where it stops

In slices. Rat hippocampus, 10 micromolar in the bath, short-term potentiation converted to long-term, dependent on protein synthesis and D1/D5 receptors Mikhaylova 2007.

In rodents. Rats, 50 mg/kg orally, single dose: region-specific changes in tyrosine hydroxylase message and protein and in dopamine and L-DOPA Mikhaylova 2007. Mice, depression-like syndrome: TNF-alpha and IL-6 reduced Tallerova 2011. The broader Soviet-era pharmacological characterization sits in Seredenin 1999.

In humans, healthy volunteers. A single 100 mg dose improved psychophysiological parameters during induced mental fatigue without behavioral toxicity, with a more pronounced effect in stress-labile individuals Bogdan 2009. That last clause is the most useful sentence in the human literature and almost nobody quotes it: the effect was larger in people who respond badly to stress, which is a responder-population claim, not a general enhancement claim.

In humans, patients. Neznamov 2009 ran a randomized blind study against placebo in neurasthenia: a wash-out period, 28 days of monotherapy with ladasten or placebo, then a final one-week placebo phase, with standardized objective and subjective mental-state instruments. Ladasten was reported superior to placebo in the rate and degree of reduction of the core asthenic symptoms, and the authors reported no withdrawal syndrome after discontinuation.

The obstacles, and there are four. (1) The diagnosis does not port. ‘Neurasthenia’ and ‘asthenic syndrome’ are live clinical categories in the Russian literature and have no DSM-5 equivalent, so the endpoint of the one controlled human trial cannot be mapped onto any Western outcome measure. (2) No independent replication. Every clinical study comes from the same institute that developed the compound. (3) The dose gap is large, and it runs the wrong way. The mechanistic rodent work used 50 mg/kg orally; converting rat to human by the standard body-surface-area factor of about 6.2 gives a human-equivalent dose near 8 mg/kg, roughly 560 mg for a 70 kg adult. The clinical and community dose is 50 to 100 mg. So people are taking something like a sixth to a tenth of the rodent-equivalent exposure that produced the tyrosine hydroxylase changes. Either the human effect works by something else, or most users are underdosed relative to the mechanism they are citing. (4) Nobody has measured a brain concentration in a person, so the 10 micromolar slice concentration cannot be compared to anything.

Bromantane pharmacokinetics — how much of it actually gets in

Start with what is missing, because the number on this card is not traceable. The half-life listed here, about 11 to 12 hours, does not correspond to any human pharmacokinetic study in the English-indexed literature. There is no published human concentration-time curve, no volume of distribution, no clearance figure and no absolute bioavailability for bromantane. That is the honest starting position, and everything below is either a measurement from another discipline or arithmetic.

What the chemistry predicts. An adamantane cage bonded to a bromophenyl ring through a secondary amine is a highly lipophilic, poorly water-soluble molecule with no ionizable group at physiological pH beyond a weakly basic arylamine. Molecules shaped like that distribute widely into fat and brain, which gives a large volume of distribution and, mechanically, a long terminal half-life — the long tail comes from redistribution out of tissue rather than from slow enzymes. Clearance for an N-aryl amine of this type runs through hepatic cytochrome P450 oxidation and conjugation rather than through renal excretion of unchanged drug, which is where amantadine differs from it.

The one hard piece of human disposition data comes from anti-doping. Bromantane surfaced as a doping agent at the 1996 Olympic Games and was characterized in urine by the laboratories that caught it Burnat 1997. That tells you it is excreted in urine in detectable form, and that the detection window is long enough to be practically useful to a testing program — which is exactly the signature of a lipophilic compound with tissue redistribution. It is an odd place to get pharmacokinetics from and it is better than nothing.

The oral route, and the arithmetic that matters most. Both the rodent mechanism study and the human studies used oral dosing Mikhaylova 2007 Bogdan 2009. The gastrointestinal barrier is not the problem for a lipophilic small molecule; the exposure gap is. 50 mg/kg in a rat versus 100 mg total in a person (about 1.4 mg/kg) is a 35-fold difference on a per-kilogram basis, or roughly 6-fold once corrected for body surface area. Nobody has measured whether a 100 mg oral dose in a human produces plasma or brain concentrations anywhere near the ones that changed tyrosine hydroxylase in a rat, and until somebody does, the mechanism and the dose are two separate stories told about the same molecule.

What would have to be true, and how you would know it was not

1. Prolactin should fall, and this is the cheapest direct test of the mechanism that exists. Dopamine is the tonic inhibitor of pituitary prolactin release. If bromantane genuinely increases dopamine synthesis capacity Mikhaylova 2007, then prolactin should drift down. Draw it fasted, mid-morning, before starting and again at 4 weeks on a steady dose, with the draw at the same clock time both times because prolactin is strongly diurnal. A measurable fall is mechanistic confirmation; no change at all, at 100 mg, is consistent with the dose gap described above.

2. The prediction that cuts against it: there should be nothing on day one. Transcriptional upregulation of a synthetic enzyme takes days, not minutes. So a person who feels a clean stimulant hit within an hour of the first dose is not experiencing the published mechanism — they are experiencing expectancy, or something else in the capsule. The corollary is equally testable and comes from the trial itself: stopping after 28 days produced no withdrawal syndrome Neznamov 2009, so a crash on discontinuation is also off-mechanism.

3. TNF-alpha should fall in someone who starts with it raised. Tallerova 2011 is a mouse study, so this is a labeled extrapolation: draw TNF-alpha and hs-CRP at baseline and 8 weeks in someone whose baseline inflammatory markers are actually elevated. Prediction: a modest fall in TNF-alpha with hs-CRP largely unchanged, because the mouse finding was cytokine-specific. If both move together, something more general is going on — weight, training load, sleep — and the compound is not the explanation.

4. The anxiolytic half should show up as a stress-response measure, not a mood score. Bogdan 2009 found the effect largest in stress-labile volunteers. So a morning cortisol at baseline and 4 weeks, plus a simple resting heart rate variability measurement from any wearable. Prediction: the people with the highest baseline cortisol show the largest change, and people with normal baselines show none — which would make this a corrective compound rather than an enhancing one, and would explain why the anecdotal record is so split.

What nobody has tested yet

Nobody has ever measured prolactin on bromantane in a human. It is on every standard hormone panel, it costs almost nothing, and it is the most direct available readout of the exact mechanism this compound is sold on. Twenty people doing paired draws would generate more human mechanistic data than the entire English-language literature on this molecule currently contains.

Nobody has published a human pharmacokinetic study. No half-life, no Cmax, no dose proportionality, no food effect. The assays exist — anti-doping laboratories have had them since 1996 Burnat 1997 — so this is a twelve-person, one-week study that would replace a widely repeated half-life figure with a measured one.

Nobody has tested the retroactive-consolidation claim in people, and it is the most interesting claim in the file. Mikhaylova 2007 showed reinforcement of potentiation when the drug arrived 40 minutes after the stimulus. The human version writes itself: a paired-associates learning task, then dose or placebo one hour after learning, then recall at 24 hours and 7 days. If post-learning dosing beats pre-learning dosing, that is a genuinely novel finding about a compound people already take.

Nobody has replicated any of the clinical work outside the institute that developed it. The controlled trial Neznamov 2009 and the volunteer study Bogdan 2009 come from the same research school. A single independent randomized trial using a Western outcome instrument — a validated fatigue scale rather than an asthenic syndrome rating — would move this compound out of the category of things that are only true in one language.

Bromantane — its own safety story, not its class's

The first practical fact: it is a prohibited substance, and there is nothing theoretical about that. Bromantane entered the world's awareness as a doping agent at the 1996 Olympic Games Burnat 1997. Anyone subject to drug testing in sport, in the military or in certain occupations will fail a test, and the detection window for a lipophilic compound is measured in days rather than hours.

The withdrawal claim, and who is making it. The one controlled human trial reported no withdrawal syndrome after 28 days and concluded there was no addictive potential Neznamov 2009. That is a real, specific, published finding and it comes from the developing institution. It is consistent with the mechanism — upregulating a synthetic enzyme does not deplete a store, so there is nothing to rebound — and it has never been checked by anyone else. Both halves of that sentence belong on the page.

The risk the mechanism actually implies is the one nobody measures: chronic upregulation of catecholamine synthesis has no measured ceiling. Every dopaminergic drug with a long human record — L-DOPA, the stimulants — runs into adaptation, receptor changes or dyskinesia over years. A compound that works upstream, at the level of how much tyrosine hydroxylase a neuron makes, might avoid all of that or might do something entirely different; the longest published human exposure is 28 days Neznamov 2009. Cycling this compound is not folklore, it is the only defensible position given that the safety data stop at four weeks.

What is missing that would be present for a Western drug. No hepatic safety monitoring data, no QT study, no drug-interaction work, and no pregnancy data. The Soviet-era pharmacological and acute toxicity characterization exists Seredenin 1999, and acute rodent toxicity is not the question a person taking 100 mg daily for a month is asking.

And the supply problem. This is sold as a research chemical. The molecule is a simple secondary arylamine on an adamantane cage — cheap to make, and cheap to make badly. The most likely impurities are synthetic intermediates including free bromoaniline derivatives, and there is no way for a buyer to detect them. Given that the dose people take is already several fold below the rodent-equivalent dose behind the mechanism, an underpotent or mislabeled product is very hard to distinguish from a compound that simply does less than advertised.

Sources read for this page

• Mikhaylova M. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.. Neuropharmacology 2007 · PMID 17854844
• Neznamov GG. [Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)].. Zh Nevrol Psikhiatr Im S S Korsakova 2009 · PMID 19491814
• Bogdan NG. [Effect of ladasten on the psychophysiological parameters of healthy volunteers].. Eksp Klin Farmakol 2009 · PMID 19642584
• Tallerova AV. Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome.. Bull Exp Biol Med 2011 · PMID 22803040
• Seredenin SB. [Analysis of pharmacological properties of bromantane].. Biull Eksp Biol Med 1999 · PMID 10640239
• Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F. Bromontan, a new doping agent.. Lancet 1997 · PMID 9314900

Bromantane — safety, predicted from mechanism

Bromantane — interference & stacking

Bloodwork to run alongside Bromantane

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Bromantane — frequently asked questions

Bromantane inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Bromantane is used for

Bromantane appears under 2 goals in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page